



 Developed by Eli Lilly and Com Checkpoint kinase 1 (CHK1) ar Regulates DNA replication and Hopefully, Prexasertib blocks C Under Phase 2 clinical trials for cancers including for patients w associated breast, ovarian, or p First CHK1 inhibitor to exhibit o monotherapy Administered via infusion so wa 	nd 2 (CHK2) inhibitor. If the repair of damaged DNA. CHK1 leading to tumor cell death r various adult and pediatric with a BRCA1/2 mutation prostate cancer objective clinical responses as a ater solubility is important
--	---

Continuous Flow Synthesis

C

Stancato, L.F. Clinical Cancer Research. 2019. 25, 2278. https://doi.org/10.1158/1078-0432.CCR-18-2728

- Large batch pharmaceutical manufacturing ill-equipped for the decreased quantity of drugs with increased potency compared to historical needs
- Small-volume continuous manufacturing allows for small batches of active _ pharmaceutical ingredients (APIs) to be manufactured in fume hoods and can easily be switched between different reactions or the apparatus can easily be disposed of and cheaply replaced
- Less exposure to hazardous materials
- Allows for gram-scale synthesis of API derivatives







 t/τ

Automated continuous flow synthesis



Automated solid-phase synthesis flow system

Amanda Milkovits





Continuous Manufacturing Using Good Manufacturing Practices



Amanda Milkovits



Prexasertib



Solid-phase Continuous Flow Synthesis Development:



Amanda Milkovits